GC-020

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameGC-020

Drug Alias Namedual anti-CD19/anti-CD20 CAR T-cell therapy (Gracell Biotechnology)anti-CD19 + anti-CD20 CAR T-cell therapy (Gracell Biotechnology)GC-020

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsB-lymphocyte antigen CD20 modulators

TargetsB-lymphocyte antigen CD19B-lymphocyte antigen CD20

Therapy Area/IndicationsLymphoma, Non-Hodgkin

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaPending

Originator CompaniesGracell Biotechnologies Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesGracell Biotechnologies Inc

Active IndicationsN/A

Inactive IndicationsLymphoma, Non-Hodgkin

Other Information

ATC CodeN/A